CN109053714A - Oxazole analog derivative and preparation method thereof and the application in pain - Google Patents

Oxazole analog derivative and preparation method thereof and the application in pain Download PDF

Info

Publication number
CN109053714A
CN109053714A CN201810924784.5A CN201810924784A CN109053714A CN 109053714 A CN109053714 A CN 109053714A CN 201810924784 A CN201810924784 A CN 201810924784A CN 109053714 A CN109053714 A CN 109053714A
Authority
CN
China
Prior art keywords
pain
analog derivative
oxazole
application
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201810924784.5A
Other languages
Chinese (zh)
Inventor
李敬敬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201810924784.5A priority Critical patent/CN109053714A/en
Publication of CN109053714A publication Critical patent/CN109053714A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Application the invention discloses a kind of oxazole analog derivative and preparation method thereof and in pain, oxazole analog derivative structural formula areWherein, R1、R2、R3、R4It is independently selected from-H or-OCH3.Compound by test has inhibitory activity well, IC of the one~example IV of embodiment to hFAAH for people and rat fat hydroamidase50Value is within the scope of 9nM to 16nM, to the IC of rFAAH50Value has selective advantage within the scope of 132nM to 152nM, illustrates that the compounds of this invention can be used for treating pain, the pain can be pain caused by postoperative pain, chronic pain, cancer pain, cancer chemotherapy, neuralgia, nociception pain, inflammatory pain.

Description

Oxazole analog derivative and preparation method thereof and the application in pain
Technical field
The invention belongs to the combinations in the fields such as pharmaceutical chemistry, Pharmaceutical Analysis, pharmaceutical preparation and pharmaceutical activity test, are related to disliking Azole derivative and preparation method thereof and the application in pain, the pain are postoperative pain, chronic pain, cancer pain, cancer Pain caused by chemotherapy, neuralgia, nociception pain, inflammatory pain.
Background technique
Pain is that body comes to harm and a kind of caused by sexual stimulus unhappy feels and emotional experience.Pain has been cited as The fifth-largest vital sign after breathing, pulse, blood pressure, body temperature.At present major part hospital individually set up Pain Management with Alleviate patient's sufferings, pain is also Neurology big event.
Fatty amide hydrolase (fatty acid amide hydrolase, FAAH) is a kind of inner membrance amide signal family Protease, be many biologically active fatty acid amide courier lipid moleculars in organism (fatty acid amides, FAAs major catalytic) hydrolyzes metabolic enzyme.Research shows that FAAH takes part in the regulation of many A signal pathways, with pain, anxiety, sleep The occurrence and development of a variety of diseases such as dormancy disorder have close relationship.It is currently based on FAAH signal path treatment pain and has become one A research hotspot.
The catalytic center of FAAH is the catalytic triads that Ser241, Ser217 and Lysl42 are constituted, and contains multiple channels And chamber, including film access channel (membrane access channel, MAC), by active site and electrodes method film surface phase Even；Cytoplasm accesses channel, and hydroaropic substance is allowed to exit activated centre (cytosolic access channel)；In conjunction with rouge The hydrophobic region of fat acid chain is known as fatty acid chain combined area (acyl chain-binding pocket, ABP), and eutectic is adjusted The fatty acid chain of body inhibitor.
Although not there is the listing of FAAH inhibitor also at present, has multiple drugs and be in clinical and preclinical bioactivity survey The examination stage.According to Thomson Reuters Cortellis statistics of database, there are multiple drugs to be in conceptual phase at present.
Summary of the invention
It is an object of the present invention to designing and providing a kind of novel oxazole analog derivative, structure is shown in formula I
Wherein, R1、R2、R3、R4It is independently selected from-H or-OCH3。
Further, novel oxazole analog derivative Formulas I specific structure is selected from:
Another object of the present invention is to provide a kind of synthetic routes of novel oxazole analog derivative Formulas I:
Further, specific synthesis step are as follows:
1) amidation process, generationization occur in a suitable solvent, compound 1 and 2,2- dimethoxy-ethane -1- amine Close object 2；
2) nucleophilic substitution generation ether namely compound 3 occur for the hydroxyl in compound 2 and bromomethyl benzene；
3) compound 3 hydrolyzes under the action of certain density hydrochloric acid, generates compound 4；
4) cyclization generation compound 5 occurs for compound 4；
5) compound 5 reacts with corresponding amine generate corresponding final product again.
Further, solvent can be methylene chloride, 1,2- dichloroethanes, second eyeball, N, N- dimethyl formyl in step 1) Amine (DMF), tetrahydrofuran, ethyl acetate, toluene, dimethylbenzene or other suitable solvents, preferably tetrahydrofuran.
Further, the range of choice of concentration of hydrochloric acid is 1mol/L~5mol/L in step 3), preferably 2mol/L.
Another object of the present invention is to provide a kind of oxazole analog derivative Formulas I or its salt to prevent, treat or assist to control Treat the application in mammal and people in fatty amide hydrolase related disease, the disease such as pain, including acute and slow Property, the pain as caused by postoperative pain, chronic pain, cancer pain, cancer chemotherapy, neuralgia, nociception pain, inflammatory pain, Backache, the pain as caused by the disease such as following various sources: diabetic neuropathy, including the thermophilic of human immunodeficiency virus Such as post herpetic neuralgia of pain caused by nervous system type viral disease, shingles zoster；Polyneuropathy, neurotoxicity, mechanical nerve Damage, complication of wrist, amynologic mechanism such as multiple sclerosis.
Another object of the present invention is to a kind of composition, including the oxazole analog derivative Formulas I and pharmaceutically acceptable Auxiliary material.
Further, inhibitors of fatty amide hydrolase described in the composition is as sole active agent.
Obviously, above content according to the present invention is not departing from this hair according to the ordinary technical knowledge and means of this field Under the premise of bright above-mentioned basic fundamental thought, the modification, replacement or change of other diversified forms can also be made.
Specific embodiment
The synthesis of embodiment one: 2- (8- (benzyloxy) -7- (3- propylpiperazine -1- base) quinoline -2- base) oxazole
1, the bromo- N- of 7- (2,2- dimethoxy-ethyl) -8-hydroxyquinoline -2- formamide synthesis:
At room temperature, to the bromo- 8-hydroxyquinoline -2- carboxylic acid (compound 1) (77.74g, 290mmol) of 7- in ethyl acetate Thionyl chloride (41.40g, 348mmol) is added in the suspension of (200mL), and is heated to reflux 3 hours.Reaction mixture is cold But it to room temperature, is diluted with tetrahydrofuran (50mL), 2,2- dimethoxy-ethane -1- amine is then added dropwise at room temperature Tetrahydrofuran (250mL) solution of (42.69g, 406mmol) and triethylamine (110mL, 789mmol).Then it is stirred at 40 DEG C It mixes reaction mixture 1 hour, is cooled to room temperature, 300mL water is added and is extracted with ethyl acetate.Organic layer is successively used 2mol/L hydrochloric acid, 10% wet chemical and water are washed.Solvent under reduced pressure is concentrated to dryness, the crude product of 89.20g is obtained The bromo- N- of 7- (2,2- dimethoxy-ethyl) -8-hydroxyquinoline -2- formamide (compound 2), yield 86.6%, without purifying, directly It connects in next step synthetic reaction.1H-NMR(400MHz,CDCl3)δ:3.32(d,2H),3.40(s,6H),4.70(t,1H), 5.43(s,1H),6.62(s,1H),7.44(d,1H),7.60(d,1H),7.71(d,1H),8.38(d,1H).13C-NMR (125MHz,CDCl3)δ:46.79,55.35,102.99,105.60,117.73,122.31,129.02,130.45,132.51, 133.38,142.91,151.85,166.77.LC-MS(ESI,pos,ion)m/z:356[M+H].
2, the synthesis of the bromo- N- of 8- (benzyloxy) -7- (2,2- dimethoxy-ethyl) quinoline-2-formamide:
By compound 2 (89.20g, 251.13mmol), potassium carbonate (35.93g, 260.0mmol), potassium iodide (4.65g, 28.00mmol), bromomethyl benzene (45.84g, 268.00mmol) is dissolved in n,N-Dimethylformamide (50.00mL), then Reaction mixture is stirred 6 hours at 90 DEG C.It is under the conditions of ice-water bath that reaction mixture is cooling, into reaction mixture according to Secondary addition 2mol/L hydrochloric acid (23.00mL), MeOH (25.00mL), water (25.00mL).The crystalline solid being collected by filtration, obtains To white crystals 8- (benzyloxy) -7- bromo- N- (2,2- dimethoxy-ethyl) quinoline-2-formamide of 101.77g, yield is 91.0%.1H-NMR(400MHz,CDCl3)δ:3.30(d,2H),3.38(s,6H),4.97(t,1H),5.13(s,2H),6.93 (s,1H),7.24-7.46(m,6H),7.56(d,1H),7.64(d,1H),8.21(d,1H).13C-NMR(125MHz,CDCl3) δ:46.79,55.35,74.56,102.99,112.40,120.61,121.87,128.16,128.17,128.19,129.01, 130.42,133.22,137.56,139.87,143.56,152.39,166.77.LC-MS(ESI,pos,ion)m/z:446[M+ H].
3, the synthesis of the bromo- N- of 8- (benzyloxy) -7- (2- oxoethyl) quinoline-2-formamide:
Compound 3 (101.77g, 228.54mmol) is dissolved in tetrahydrofuran (120mL) solution, then into this solution The hydrochloric acid (116mL, 231mmol) of 2mol/L is added, and is stirred 3 hours at 50 DEG C.Then reaction mixture is cooled to room Temperature adds water (90mL), is extracted with ethyl acetate, organic layer is then washed with water twice.It is different with two after solvent is concentrated under reduced pressure Propyl ether mashing, obtains white crystal 8- (benzyloxy) -7- bromo- N- (2- oxoethyl) quinoline-2-formamide (chemical combination of 72.81g Object 4), yield 79.8%.1H-NMR(400MHz,CDCl3)δ:3.88(d,1H),4.13(d,1H),5.16(s,2H),6.10 (s,1H),7.28-7.50(m,6H),7.60(d,1H),7.68(d,1H),8.25(d,1H),9.72(t,1H).13C-NMR (125MHz,CDCl3)δ:42.75,74.56,112.40,120.61,121.87,128.16,128.17,128.19,129.01, 130.42,133.22,137.56,139.87,143.56,152.39,165.70,194.28.LC-MS(ESI,pos,ion)m/ z:400[M+H].
4, the synthesis of 2- (8- (benzyloxy) -7- bromoquinoline -2- base) oxazole:
At room temperature, to the compound 4 (72.81g, 182.37mmol) and carbon trichloride being dissolved in acetonitrile (60mL) Triphenylphosphine (95.67g, 364.74mmol) is added in the suspension of (86.34g, 364.74mmol), then stirs 25 minutes, It is added triethylamine (50.70mL, 364.74mmol).Then reaction mixture is stirred at room temperature 3 hours, and at 50 DEG C again Then stirring 3 hours reheats reflux 8 hours.After reaction mixture is cooled to room temperature, it is added water (50mL), and use acetic acid Ethyl ester extraction.Organic layer is successively used into salt water and water washing.After solvent is concentrated under reduced pressure, is recrystallized, obtained with methanol/water White crystals 2- (8- (benzyloxy) -7- bromoquinoline -2- base) oxazole (compound 5) of 59.10g, yield 85.0%.1H-NMR (400MHz,CDCl3)δ:5.16(s,2H),7.15(d,1H),7.28-7.50(m,7H),7.60(d,1H),7.65(d,1H), 7.99(dd,1H).13C-NMR(125MHz,CDCl3)δ:74.56,112.40,120.61,120.92,128.16,128.19, 129.01,129.98,130.38,130.42,137.21,137.56,139.05,140.05,143.46,152.39, 157.98.LC-MS(ESI,pos,ion)m/z:382[M+H].
5, the synthesis of 2- (8- (benzyloxy) -7- (3- propylpiperazine -1- base) quinoline -2- base) oxazole:
Under an argon atmosphere, acid chloride (2.40g) is added into the toluene suspension of 3- propylpiperdine (11.2g), to first Benzene sulfonic acid sodium salt (3.90g), toluene (37mL) solution of sodium tert-amyl alcohol (11.8g), two adamantane butyl phosphines (7.70g), and It stirs 1 hour at room temperature.In reaction suspension, compound 5 (19.10g, 50.10mmol) and first are added under the conditions of ice-water bath Benzene (33mL) is then heated to reflux 4 hours.Reaction mixture is cooled to room temperature after the reaction was completed, 2mol/L hydrochloric acid is added (37.5mL).The precipitating to be formed is collected by filtration, obtains light brown crystalline 2- (8- (benzyloxy) -7- (3- propyl piperazine of 17.14g Piperazine -1- base) quinoline -2- base) oxazole, yield 80.0%.1H-NMR(400MHz,CDCl3)δ:0.89(t,3H),1.09-1.23 (m,3H),1.31-1.82(m,6H),3.20-3.41(m,3H),3.50(m,1H),5.16(s,2H),6.78(d,1H),7.15 (d,1H),7.25-7.50(m,6H),7.60(d,1H),7.85(dd,1H),8.10(d,1H).13C-NMR(125MHz,CDCl3) δ:14.20,20.79,23.04,29.52,35.58,35.82,49.96,54.26,74.56,116.65,119.16,122.34, 128.16,128.19,129.01,130.13,130.38,136.75,137.21,137.56,138.02,138.52,145.04, 146.40,157.98.LC-MS(ESI,pos,ion)m/z:428[M+H].
The conjunction of embodiment two: 2- (8- (benzyloxy) -7- (3- methoxyl group -5- propylpiperazine -1- base) quinoline -2- base) oxazole At
Under an argon atmosphere, acid chloride is added into the toluene suspension of 3- methoxyl group -5- propylpiperdine (52mmol) Toluene (37mL) solution, the two adamantane butyl phosphines of (2.40g), p-methyl benzenesulfonic acid sodium salt (3.90g), sodium tert-amyl alcohol (11.8g) (7.70g), and be stirred at room temperature 1 hour.In reaction suspension, under the conditions of ice-water bath be added compound 5 (19.10g, 50.10mmol) with toluene (33mL), then it is heated to reflux 4 hours.Reaction mixture is cooled to room temperature after the reaction was completed, is added Enter 2mol/L hydrochloric acid (37.5mL).The precipitating to be formed is collected by filtration, obtains the light brown crystalline 2- (8- (benzyloxy)-of 19.03g 7- (3- methoxyl group -5- propylpiperazine -1- base) quinoline -2- base) oxazole, yield 83%.LC-MS(ESI,pos,ion)m/z:458 [M+H].
The conjunction of embodiment three: 2- (8- (benzyloxy) -7- (4- methoxyl group -5- propylpiperazine -1- base) quinoline -2- base) oxazole At
Under an argon atmosphere, acid chloride is added into the toluene suspension of 4- methoxyl group -5- propylpiperdine (52mmol) Toluene (37mL) solution, the two adamantane butyl phosphines of (2.40g), p-methyl benzenesulfonic acid sodium salt (3.90g), sodium tert-amyl alcohol (11.8g) (7.70g), and be stirred at room temperature 1 hour.In reaction suspension, under the conditions of ice-water bath be added compound 5 (19.10g, 50.10mmol) with toluene (33mL), then it is heated to reflux 4 hours.Reaction mixture is cooled to room temperature after the reaction was completed, is added Enter 2mol/L hydrochloric acid (37.5mL).The precipitating to be formed is collected by filtration, obtains the light brown crystalline 2- (8- (benzyloxy)-of 18.57g 7- (4- methoxyl group -5- propylpiperazine -1- base) quinoline -2- base) oxazole, yield 81%.LC-MS(ESI,pos,ion)m/z:458 [M+H].
Example IV: 2- (8- (benzyloxy) -7- (2,5- dimethoxy -3- propylpiperazine -1- base) quinoline -2- base) oxazole Synthesis
Under an argon atmosphere, acetic acid is added into the toluene suspension of 2,5- dimethoxy -3- propylpiperdine (52mmol) Palladium (2.40g), p-methyl benzenesulfonic acid sodium salt (3.90g), sodium tert-amyl alcohol (11.8g) toluene (37mL) solution, two adamantane butyl Phosphine (7.70g), and be stirred at room temperature 1 hour.In reaction suspension, under the conditions of ice-water bath be added compound 5 (19.10g, 50.10mmol) with toluene (33mL), then it is heated to reflux 4 hours.Reaction mixture is cooled to room temperature after the reaction was completed, is added Enter 2mol/L hydrochloric acid (37.5mL).The precipitating to be formed is collected by filtration, obtains the light brown crystalline 2- (8- (benzyloxy)-of 18.32g 7- (2,5- dimethoxy -3- propylpiperazine -1- base) quinoline -2- base) oxazole, yield 75%.LC-MS(ESI,pos,ion)m/ z:488[M+H]。
Test example: people and rat fat amide hydrolysis enzyme inhibition activity
For the compounds of this invention to people and rat fat hydroamidase (FAAH) inhibitory activity, test method is same CN103958473B, unless otherwise stated, all reagents are purchased from Sigma.It is summarized as follows:
Material and reagent:
For the people of analysis and rat fat hydroamidase (FAAH) gene by Patricelli etc. (Biochemistry.1998,37 (43), 15177-87) description.Fatty amide hydrolase (FAAH) gene that transmembrane domain is deleted It is cloned into pET15b (Novagen, #69661) (people FAAH)/pET28a (Novagen, #69864-3) (rat FAAH gene) matter It is expressed in grain and in Escherichia coli (Ecoli) BL21DE3.Companion's egg in pGR07 plasmid (Takara Bio Inc, Japan) White groEL-groES and fatty amide hydrolase (FAAH) are co-expressed, so as to improve expression in escherichia coli protein it is molten Xie Du.It is recorded in such as Mileni (Proc NatlAcad Sci USA.2008,105 (35), 12820-4), to express simultaneously Enrichment protein.In short, using arabinose (2mM) and isopropyl ss-D-1- thiogalactoside (IPTG) (1mM) at room temperature Induce the bacterial cultures 20h in LB culture medium (Luria Broth) (2L).Culture is centrifuged 10min at 1200 × g, And by cell mass (cell pellet) be resuspended in 100mL NaPi containing 20mM (pH7.4), 100mM NaCl, nuclease (500u), In the buffer of Aprotinin (1 μ g/mL) and leupeptin (1 μ g/mL).Pass through sonic method (Amp 20%, pulse 15s × 15, ice On) lytic cell, and cell fragment is removed by being centrifuged 20min under 5000 × g.Suspension exceeded the speed limit under 100,000 × g from The heart 1h enrichment, and by cell mass be resuspended in 16mL NaPi containing 20mM (pH7.8), 500mM NaCl, 1% triton x-100 delay In fliud flushing.The cell extract of suspension carries out ultracentrifugation 1h under 100,000 × g, and the suspension of enrichment is used in vitro Analysis.All proteins extraction step carries out on ice or at 4 DEG C.
Analyzed in vitro:
The bioactivity of compound is evaluated using fluorescence-based analysis, thus quantitative arachidonic base 7- amino, 4 first Butylcoumariii amide (AAMCA), fatty amide hydrolase (FAAH) fluorogenic substrate hydrolysis (Anal Biochem.2005, 343 (1): 143-51).With the progress of 200 μ L volumes in 96 hole black polystyrene plates (Greiner Bio-one, Germany) Analysis.Each reaction by HEPES containing 50mM, 1mM EDTA and 0.1%BSA (PH7.4) analysis buffer in people's fatty acid amide Hydrolase (FAAH) albumen and 10 μM of AAMCA are constituted.With the inhibitor (final concentration of DMSO of 2 μ L various concentrations in DMSO 1%) oscillation while incubation reaction 1min and in 50min monitor kinetics model in fluorescence increase.In excitation wavelength Under 355nm and 460nm transmitting under, using Flexstation III microplate reader (Molecular Devices, Sunnyvale, CA the increase of fluorescence) is measured.The reaction rate of function used as inhibitor concentration measures the IC of inhibitor50.It uses Graph PadPrism (Graph Pad Software Inc., San Diego, CA) analyzes data.Rat is utilized as described above Fatty amide hydrolase (FAAH) albumen and 10 μM of AAMCA substrate evaluation compounds are to rat fat hydroamidase (FAAH) Activity.
1 the compounds of this invention of table is to people and rat FAAH inhibitory activity.
hFAAH IC50(nM) rFAAH IC50(nM)
Embodiment one 9 132
Embodiment two 13 140
Embodiment three 15 144
Example IV 16 152
OL-135 12 83
Inhibit to live well the result shows that the compound by test has people and rat fat hydroamidase Property, inhibitory activity IC of the positive control OL-135 to people and rat fat hydroamidase50Value is respectively 12nM and 83nM.Implement IC of the one~example IV of example to hFAAH50Value is within the scope of 9nM to 16nM, to the IC of rFAAH50Value is in 132nM to 152nM model In enclosing, there is selective advantage.Illustrate that the compound of the present invention can be used as inhibitors of fatty amide hydrolase and carry out subsequent grind It sends out, the disease such as pain paid close attention in R&D process, including acute and chronic, such as postoperative pain, chronic pain, carcinous pain Bitterly, pain caused by cancer chemotherapy, neuralgia, nociception pain, inflammatory pain, backache, by the disease in such as following various sources Caused pain: diabetic neuropathy, the thermophilic nervous system type viral disease including human immunodeficiency virus, shingles zoster draw The pain such as post herpetic neuralgia risen；Polyneuropathy, neurotoxicity, mechanical neurotrosis, complication of wrist, amynologic mechanism are such as Multiple sclerosis.

Claims (5)

1. a kind of oxazole analog derivative, structure are shown in formula I
Wherein, R1、R2、R3、R4It is independently selected from-H or-OCH3。
2. the synthetic route route of oxazole analog derivative Formulas I as described in claim 1 is
3. oxazole analog derivative Formulas I as described in claim 1 or its salt are preventing, treating or are assisting in the treatment of mammal and people Application in middle fatty amide hydrolase related disease.
4. the application of oxazole analog derivative Formulas I as described in claim 1 or its salt in the drug for the treatment of pain.
5. application as claimed in claim 4, characterized in that the pain is selected from postoperative pain, chronic pain, cancer pain, cancer Pain caused by chemotherapy, neuralgia, nociception pain, inflammatory pain.
CN201810924784.5A 2018-08-14 2018-08-14 Oxazole analog derivative and preparation method thereof and the application in pain Withdrawn CN109053714A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810924784.5A CN109053714A (en) 2018-08-14 2018-08-14 Oxazole analog derivative and preparation method thereof and the application in pain

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810924784.5A CN109053714A (en) 2018-08-14 2018-08-14 Oxazole analog derivative and preparation method thereof and the application in pain

Publications (1)

Publication Number Publication Date
CN109053714A true CN109053714A (en) 2018-12-21

Family

ID=64678392

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810924784.5A Withdrawn CN109053714A (en) 2018-08-14 2018-08-14 Oxazole analog derivative and preparation method thereof and the application in pain

Country Status (1)

Country Link
CN (1) CN109053714A (en)

Similar Documents

Publication Publication Date Title
CA2965981C (en) Substituted chromanes and method of use
US8993612B2 (en) Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
US9981918B2 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
ES2590804T3 (en) Imidazopyrazine Syk inhibitors
CN104284893B (en) Liver X receptor (LXR) modulators for the treatment of dermal diseases, disorders and conditions
US20060183746A1 (en) Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US10399971B2 (en) Compound for treating or preventing hyperuricemia or gout
US20210069182A1 (en) Ror-gamma modulators
WO2018222917A1 (en) Ire1 small molecule inhibitors
Hou et al. Design, synthesis and biological evaluation of carbohydrate-based sulphonamide derivatives as topical antiglaucoma agents through selective inhibition of carbonic anhydrase II
Katiyar et al. Syntheses of 2, 4, 6-trisubstituted pyrimidine derivatives as a new class of antifilarial topoisomerase II inhibitors
US20220135567A1 (en) Tyk2 pseudokinase ligands
TW200410695A (en) Quinazolinone derivatives useful as anti-hyperalgesic agents
US20220298176A1 (en) Heteroaryl plasma kallikrein inhibitors
JP2024507596A (en) Triazole derivatives and their production methods and uses
Ahmad et al. Synthesis of novel benzofuran isoxazolines as protein tyrosine phosphatase 1B inhibitors
US20230331718A1 (en) Compositions for modulating splicing
JP4245682B2 (en) Quinoline derivatives, isoquinoline derivatives, and cinnoline derivatives, and anti-inflammatory and anti-allergic agents
Li et al. Identification and structure–activity relationship exploration of uracil-based benzoic acid and ester derivatives as novel dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus
CN108191770B (en) 2, 3-phthalazinone or 2, 3-naphthyridine derivatives and uses thereof
WO2021104072A1 (en) Hydrogen peroxide-responsive keap1-nrf2 ppi inhibitor prodrug, preparation method therefor, and pharmaceutical use thereof
ES2804304T3 (en) Hepatic X receptor (LXR) modulators
US9981913B2 (en) Liver X receptor (LXR) modulators
CN111499591A (en) ROR gamma modulators
CN109053714A (en) Oxazole analog derivative and preparation method thereof and the application in pain

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20181221